File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Prevalence and prognostic impact of comorbidities in sarcomas: A population-based study of 3746 patients in Hong Kong

TitlePrevalence and prognostic impact of comorbidities in sarcomas: A population-based study of 3746 patients in Hong Kong
Authors
Issue Date2019
PublisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/
Citation
2019 the Japanese Society of Medical Oncology (JSMO) Annual Meeting, Kyoto, Japan, 18–20 July 2019. In Annals of Oncology, v. 30 n. Supp. 6, article no. mdz339.024 How to Cite?
AbstractBackground The prognostic impact of comorbidities in patients (pts) with sarcomas is not well defined. The aims of this study were to examine the prevalence of comorbidities and its impact on overall survival in pts with sarcomas. Methods A population-based retrospective database was assembled to extract pts with sarcoma, as defined as ICD-9-CM codes of bone (170.x) or/and soft tissue (171.x) who have attended clinics or hospitals of the Hong Kong Hospital Authority between Jan 2004 and Mar 2018. Eligible pts with index presentation of bone or/and soft tissue sarcoma (STS) on or after Jan 2005 were analysed to allow 1-year window period. Comorbidities were obtained, and Charlson’s Comorbidity Score (CCS) defined by 19 medical conditions according to risk of mortality at the time of sarcoma diagnosis was calculated. CCS score and prevalence of comorbidities at diagnosis were assessed. Rate of all-cause mortality according to level of CCS were computed. The prognostic value of CCS was estimated using Cox proportional hazard models. Results Of 3746 pts identified, 3358 pts satisfied eligibility: bone: n = 661, STS: n = 2576; both: n = 121. Male: Female 52.6%: 47.4%. Proportional age group: <18 years (y): 7.56% (n = 254); 18<40y: 15.7% (n = 529); 40<65y: 42.2% (n = 1418); 65<80y: 23.4% (n = 787); >/=80y: 11.0% (n = 370). Top 5 common co-morbidities: diabetes mellitus (9.8%); cerebrovascular disease (4.8%), ischaemic heart disease (3.8%), chronic lung disease (2.9%), congestive heart failure (2.6%). Mean age at presentation: 54.2y (bone: 46.8y, STS: 56.5y). Mean CCS: 4.6. Pts with higher CCS had higher mortality (CCS3 vs. CCS2; HR 1.49; 95% CI 1.19-1.87; p < 0.01; CCS>/=7 vs. CCS2; HR 3.20; 95% CI: 2.62-3.92; p < 0.001). Conclusions This is the largest population-based sarcoma cohort reported from Asia. Presence of comorbidities have significant negative prognostic impact on pts with sarcomas. Identification and treatment of relevant comorbidities may improve survival of sarcoma pts.
DescriptionOral abstract session 2-5 : Rare Cancer (Soft Tissue Sarcoma)
Persistent Identifierhttp://hdl.handle.net/10722/279028
ISSN
2017 Impact Factor: 13.93
2015 SCImago Journal Rankings: 4.362

 

DC FieldValueLanguage
dc.contributor.authorLoong, HHF-
dc.contributor.authorWong, CKH-
dc.contributor.authorHo, CW-
dc.contributor.authorTse, T-
dc.contributor.authorKwan, SSC-
dc.contributor.authorLau, YM-
dc.contributor.authorLeung, LKS-
dc.date.accessioned2019-10-21T02:18:18Z-
dc.date.available2019-10-21T02:18:18Z-
dc.date.issued2019-
dc.identifier.citation2019 the Japanese Society of Medical Oncology (JSMO) Annual Meeting, Kyoto, Japan, 18–20 July 2019. In Annals of Oncology, v. 30 n. Supp. 6, article no. mdz339.024-
dc.identifier.issn0923-7534-
dc.identifier.urihttp://hdl.handle.net/10722/279028-
dc.descriptionOral abstract session 2-5 : Rare Cancer (Soft Tissue Sarcoma)-
dc.description.abstractBackground The prognostic impact of comorbidities in patients (pts) with sarcomas is not well defined. The aims of this study were to examine the prevalence of comorbidities and its impact on overall survival in pts with sarcomas. Methods A population-based retrospective database was assembled to extract pts with sarcoma, as defined as ICD-9-CM codes of bone (170.x) or/and soft tissue (171.x) who have attended clinics or hospitals of the Hong Kong Hospital Authority between Jan 2004 and Mar 2018. Eligible pts with index presentation of bone or/and soft tissue sarcoma (STS) on or after Jan 2005 were analysed to allow 1-year window period. Comorbidities were obtained, and Charlson’s Comorbidity Score (CCS) defined by 19 medical conditions according to risk of mortality at the time of sarcoma diagnosis was calculated. CCS score and prevalence of comorbidities at diagnosis were assessed. Rate of all-cause mortality according to level of CCS were computed. The prognostic value of CCS was estimated using Cox proportional hazard models. Results Of 3746 pts identified, 3358 pts satisfied eligibility: bone: n = 661, STS: n = 2576; both: n = 121. Male: Female 52.6%: 47.4%. Proportional age group: <18 years (y): 7.56% (n = 254); 18<40y: 15.7% (n = 529); 40<65y: 42.2% (n = 1418); 65<80y: 23.4% (n = 787); >/=80y: 11.0% (n = 370). Top 5 common co-morbidities: diabetes mellitus (9.8%); cerebrovascular disease (4.8%), ischaemic heart disease (3.8%), chronic lung disease (2.9%), congestive heart failure (2.6%). Mean age at presentation: 54.2y (bone: 46.8y, STS: 56.5y). Mean CCS: 4.6. Pts with higher CCS had higher mortality (CCS3 vs. CCS2; HR 1.49; 95% CI 1.19-1.87; p < 0.01; CCS>/=7 vs. CCS2; HR 3.20; 95% CI: 2.62-3.92; p < 0.001). Conclusions This is the largest population-based sarcoma cohort reported from Asia. Presence of comorbidities have significant negative prognostic impact on pts with sarcomas. Identification and treatment of relevant comorbidities may improve survival of sarcoma pts.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/-
dc.relation.ispartofAnnals of Oncology-
dc.rightsPre-print: Journal Title] ©: [year] [owner as specified on the article] Published by Oxford University Press [on behalf of xxxxxx]. All rights reserved. Pre-print (Once an article is published, preprint notice should be amended to): This is an electronic version of an article published in [include the complete citation information for the final version of the Article as published in the print edition of the Journal.] Post-print: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in [insert journal title] following peer review. The definitive publisher-authenticated version [insert complete citation information here] is available online at: xxxxxxx [insert URL that the author will receive upon publication here].-
dc.titlePrevalence and prognostic impact of comorbidities in sarcomas: A population-based study of 3746 patients in Hong Kong-
dc.typeConference_Paper-
dc.identifier.emailWong, CKH: carlosho@hku.hk-
dc.identifier.emailHo, CW: hochuwa@hku.hk-
dc.identifier.authorityWong, CKH=rp01931-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/annonc/mdz339.024-
dc.identifier.hkuros307302-
dc.identifier.volume30-
dc.identifier.issueSupp. 6-
dc.identifier.spagearticle no. mdz339.024-
dc.identifier.epagearticle no. mdz339.024-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats